Valneva Se (VALN) has released an update.
Valneva SE, a specialty vaccine company, has filed its 2023 Universal Registration Document and its Form 20-F with France’s AMF and the U.S. SEC, respectively. The documents, containing annual financial and sustainability reports, are available on Valneva’s website and through the AMF and SEC, with hard copies obtainable upon request. Valneva, known for its travel vaccines including the only chikungunya vaccine, is also advancing a Lyme disease vaccine candidate in partnership with Pfizer.
For further insights into VALN stock, check out TipRanks’ Stock Analysis page.
